publications

ASCO 2026 spotlight: The data making headlines 

July 2, 2026
Author: Abby Kim, PharmD, BCOP
From potential new standards of care to unexpected innovations reshaping treatment paradigms, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting highlighted advances that could transform oncology practice. Here, we examine the data, impacts and implications for the evolving managed-care landscape. 
 

Prostate cancer: Raising the bar for perioperative therapy 

Despite curative-intent surgery, patients with high-risk localized or locally advanced prostate cancer remain at significant risk for recurrence and metastatic progression. The Phase 3 PROTEUS trial evaluated whether intensifying treatment with perioperative apalutamide (APA) plus androgen deprivation therapy (ADT) could improve outcomes compared with placebo plus ADT in patients undergoing radical prostatectomy. APA plus ADT reduced the risk of recurrence, progression or death by 29% (event-free survival hazard ratio [EFS HR], 0.71) and lowered the risk of metastasis or death by 20%. Patients receiving APA were also nearly 10 times more likely to achieve a pathologic complete response (pCR) or minimal residual disease at surgery. With improvements across all key efficacy endpoints, PROTEUS provides some of the strongest evidence to date that systemic treatment intensification can improve long-term outcomes in high-risk localized prostate cancer and may establish a new perioperative standard of care.¹
Impact to payers: The PROTEUS trial signals a potential shift toward treatment intensification in earlier-stage prostate cancer. An improved pCR and reduction in recurrence may translate into longer periods free from disease progression or metastasis. For payers, this adoption could lead to higher upfront treatment costs, offset by future reductions in recurrence, metastasis or subsequent lines of therapy.¹ 
 

Pancreatic cancer: A long-awaited advance in a difficult-to-treat disease 

Despite decades of research, metastatic pancreatic adenocarcinoma (mPDAC) remains one of the deadliest cancers, with limited treatment options after progression on first-line therapy. In the Phase 3 RASolute-302 trial, the oral RAS(ON) inhibitor daraxonrasib was compared with chemotherapy as second-line treatment for mPDAC. Daraxonrasib delivered one of the most notable results presented at ASCO 2026, earning a rare standing ovation after doubling median overall survival from 6.6 months to 13.2 months versus chemotherapy (P<0.0001). In addition, daraxonrasib demonstrated lower rates of treatment discontinuation, reflecting improved tolerability versus chemotherapy. Given the magnitude of survival benefit in a disease where therapeutic advances have historically been limited, RASolute-302 may represent one of the most significant developments in pancreatic cancer treatment to date and is likely to establish daraxonrasib as a new standard of care.² 
Impact to payers: RASolute-302 has the potential to reshape expectations for second-line pancreatic cancer treatment. A doubling of overall survival is rarely observed in mPDAC and represents a meaningful advancement for a patient population with historically poor outcomes. For providers, these findings will accelerate adoption and reduce reliance on traditional chemotherapy in the second-line setting. For payers, daraxonrasib introduces a notable shift in site of care and benefit design. Today, second-line mPDAC treatment is largely driven by infused chemotherapy, covered under the medical benefit. If approved, an effective oral, targeted therapy would move a portion of treatment utilization and costs to the pharmacy benefit while potentially improving outcomes and reducing treatment discontinuations compared with chemotherapy.² ³
 

Breast cancer: A new frontier for selective estrogen receptor degraders (SERDs) in early disease  

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounts for approximately 70% of all breast cancer diagnoses, and adjuvant endocrine therapy with tamoxifen or aromatase inhibitors (AI) has remained largely unchanged for decades.⁴ While SERDs have demonstrated efficacy in advanced and metastatic breast cancer, they have not been established in early-stage disease. In the Phase III lidERA trial, the oral SERD giredestrant was compared with physician's choice endocrine therapy, including tamoxifen or AI, in patients with early-stage breast cancer. Giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard endocrine therapy (invasive disease-free survival [iDFS] HR, 0.70). The agent also demonstrated favorable tolerability and lower treatment discontinuation rates, potentially addressing one of the long-standing challenges of adjuvant endocrine therapy. As the first Phase III study to demonstrate superiority over established endocrine therapies in the adjuvant setting, lidERA may open a new frontier for SERDs in curative-intent breast cancer.⁵ 
Impact to payers: The lidERA results suggest that recurrence risk may be further reduced for patients with early-stage breast cancer. For payers, the implications may be significant. Current adjuvant endocrine therapy is dominated by low-cost generic agents covered under the pharmacy benefit. If approved, giredestrant would remain a pharmacy-benefit product but could substantially increase spending in one of the largest breast cancer populations. The magnitude of benefit demonstrated in lidERA will likely drive discussion regarding value, access and formulary-management strategies.⁶ 
 

Glucagon-like peptide-1 (GLP-1) receptor agonists: Here to stay 

Last year, we highlighted emerging evidence linking GLP-1 therapies to reduced risk in obesity-related cancers. At ASCO 2026, research continued to explore their potential role across the cancer continuum. In a real-world analysis of breast cancer patients, GLP-1 use was associated with a 63% reduction in the risk of post-mastectomy lymphedema (HR, 0.373; P<0.0001). Another study found a 25%–37% lower risk of breast cancer among women receiving GLP-1 therapies (odds ratio [OR], 0.63–0.75). While these findings remain exploratory, they add to a growing body of evidence suggesting GLP-1 therapies may exert effects beyond weight loss, potentially through anti-inflammatory and other disease-modifying mechanisms.⁷ ⁸ 
Impact to payers: Although not yet practice-changing, these findings are expanding the conversation around the long-term value of GLP-1 therapies. For patients, the potential benefits of GLP-1s may extend beyond diabetes and weight management into broader health outcomes. Providers should expect continued research evaluating their role in cancer prevention, survivorship and disease modification. For payers, emerging evidence of potential reductions in cancer incidence and cancer-related complications could further influence assessments of the overall value proposition of GLP-1 therapies as evidence continues to mature.⁷⁻⁹ 
 
These highlights represent just a glimpse of the groundbreaking data presented at the 2026 ASCO Annual Meeting. With many more studies presented and poised to reshape clinical practice, we can look forward to continued innovation and insights at next year's gathering. 
 

References 

  1. Taplin, M.-E., Gleave, M., Shore, N. D., Lopez-Gitlitz, A., Kretschmer, A., Efstathiou, E., Damião, R., Kamoto, T., Ross, A., Briganti, A., Hadaschik, B. A., Heidenreich, A., Juárez Soto, Á., Rooney, O. B., Tian, S. K., Wetherhold, L., Miladinovic, B., McCarthy, S., Evans, C. P., & Kibel, A. S. (2026). Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study. Journal of Clinical Oncology, 44(17_suppl), LBA1. https://doi.org/10.1200/JCO.2026.44.17_suppl.LBA1 
  2. Wolpin, B. M., Wainberg, Z. A., Hendifar, A., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., Garrido-Laguna, I., Springfeld, C., Azad, N. S., Ueno, M., Chui, S. Y., Zhang, Y., Patel, H., Lee, Y., Salman, Z., & O’Reilly, E. M. (2026). Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study. Journal of Clinical Oncology, 44(17_suppl), LBA5. https://doi.org/10.1200/JCO.2026.44.17_suppl.LBA5 
  3. American Cancer Society. (2026, January 13). Survival rates for pancreatic cancer. https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html 
  4. American Cancer Society. (2024). Breast cancer facts & figures 2024–2025. https://www.cancer.org/research/cancer-facts-statistics/breast-cancer-facts-figures.html 
  5. Roche. (2025, December 10). Giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer. https://www.roche.com/media/releases/med-cor-2025-12-10 
  6. IPD Analytics. (2026). Highlights from American Society of Clinical Oncology 2026. (Subscription required) 
  7. McDonald, E. S., Gillis, L., Gabriel, P., Xapakdy, K., Young, A. J., Schnall, M. D., & Pisano, E. (2026). Association of GLP-1 agonists with breast cancer incidence in women. Journal of Clinical Oncology, 44(16_suppl), 10506. https://doi.org/10.1200/JCO.2026.44.16_suppl.10506 
  8. Yesho, D.H., Megiso, M., Ugwu, C., Neely, A.N., Obomanu, E., Verinumbe, T., & Jones, C. (2026). GLP-1 RA for primary prevention of post-mastectomy lymphedema in breast cancer patients: A multicenter real-world analysis. Journal of Clinical Oncology, 44(16_suppl), 628. https://doi.org/10.1200/jco.2026.44.16_suppl.628 
  9. Muir, L. (2026, January 29). How many American women are using GLP-1 medications? North American Community Hub. https://nchstats.com/american-women-glp-1-medications-use/